Joseph Monahan - Oct 23, 2023 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Scientific Officer
Signature: /s/ Mark Ballantyne, Attorney-in-fact
Stock symbol: ACRS
Transactions as of: Oct 23, 2023
Transactions value $: -$30,460
Form type: 4
Date filed: 10/25/2023, 04:28 PM
Previous filing: Aug 22, 2023
Next filing: Feb 5, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Sale	-$30.5K	-6K	-4.42%	$5.08	130K	Oct 23, 2023	Direct	F1, F2
holding	ACRS	Common Stock						193	Oct 23, 2023	By Spouse

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2023.
F2	The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $4.97 to $5.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2023.

The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $4.97 to $5.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.